Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | CD38 | P28907 | 4/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | WNT1 | P04628 | 2/20 | 0.31 |
| ▸ | GSK3B | P49841 | 2/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31377330 | 0.91 | GPR119 (0.42) | GPR119HCRTR1HCRTR2DPP4CD38 | |
| SCHEMBL32687070 | 0.90 | GPR119 (0.40) | GPR119HCRTR1HCRTR2DPP4CD38 | |
| SCHEMBL32687718 | 0.90 | GPR119 (0.41) | GPR119HCRTR1HCRTR2DPP4NR1H2 | |
| SCHEMBL32687326 | 0.89 | GPR119 (0.40) | GPR119HCRTR1HCRTR2DPP4WNT1 | |
| SCHEMBL31377329 | 0.89 | GPR119 (0.44) | GPR119HCRTR1HCRTR2DPP4CD38 | |
| SCHEMBL32687131 | 0.86 | GPR119 (0.39) | GPR119HCRTR1HCRTR2DPP4WNT1 | |
| SCHEMBL31421087 | 0.82 | GPR119 (0.36) | GPR119HCRTR1HCRTR2DPP4 | |
| SCHEMBL32687120 | 0.82 | GPR119 (0.37) | GPR119HCRTR1HCRTR2 | |
| SCHEMBL32687248 | 0.81 | NR1H2 (0.33) | GPR119DPP4NR1H2NR1H3 | |
| SCHEMBL31420802 | 0.78 | DPP4 (0.34) | GPR119DPP4NR1H2NR1H3USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109696-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260078116-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2026-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078116-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, MCL1 | GPR119 3997/4885HCRTR1 4584/4885HCRTR2 4397/4885 |
| US-20260109696-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | KRAS, MYC, NRAS | GPR119 3752/4885HCRTR1 3614/4885HCRTR2 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.